公开(公告)号：EP3292104A1

公开(公告)日：2018-03-14

申请号：EP16720441.1

申请日：2016-05-04

申请人： Astrazeneca AB

发明人： RONN, Robert ,  LINDH, Carl, Jonas ,  RINGBERG, Erik ,  ANDERSSON, Hanna, Birgitta, Ellinor ,  NILSSON, Peter ,  SCHAAL, Wesley, Ralph ,  MUNCK AF ROSENSCHÖLD, Magnus ,  NIKITIDIS, Antonios ,  NIKITIDIS, Grigorios ,  JOHANNESSON, Petra ,  TYRCHAN, Christian

IPC分类号： C07D213/74 ,  C07D401/08 ,  C07D239/42 ,  C07D241/20 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/505 ,  A61P11/00 ,  A61P29/00

CPC分类号： A61K31/4965 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/505 ,  C07C211/55 ,  C07C211/58 ,  C07D213/74 ,  C07D215/38 ,  C07D239/42 ,  C07D239/47 ,  C07D241/20 ,  C07D401/08 ,  C07D401/12 ,  C07D405/12

摘要： wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.